Figure 7
Addition of CCI-779 to cetuximab potentiates the inhibitory effect on cell survival in HNSCC cells with acquired resistance to cetuximab. Cell viability of cisplatin-resistant cells (upper panels, dashed lines) can only be slightly increased in the FaDuCDDP-R model when combining CCI-779 with cisplatin (solid lines) compared to CCI-779 single treatment. In cetuximab-resistant cells (lower panels, dashed lines), the addition of cetuximab to CCI-779 further decreases cell viability in both models (solid lines).